Targeting CDC7 sensitizes resistance melanoma cells to BRAFV600E-specific inhibitor by blocking the CDC7/MCM2-7 pathway
Open Access
- 2 October 2019
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-12
Abstract
Although the utilization of selective BRAFV600E inhibitors is associated with improved overall survival in patients with metastatic melanoma, a growing challenge of drug resistance has emerged. CDC7 has been shown to be overexpressed and associated with poor prognosis in various cancers including melanoma. Thus, we aimed to elucidate the biological role of CDC7 in promoting Vemurafenib resistance and the anticipated benefits of dual targeting of BRAFV600E and CDC7 in melanoma cells. We performed exosomes-associated microRNA profiling and functional assays to determine the role of CDC7 in drug resistance using Vemurafenib-sensitive and resistant melanoma cells. Our results demonstrated that Vemurafenib-resistant cells exhibited a persistent expression of CDC7 in addition to prolonged activity of MCM2 compared to drug-sensitive cells. Reconstitution of miR-3613-3p in resistant cells downregulated CDC7 expression and reduced the number of colonies. Treatment of cells with low concentrations of CDC7 inhibitor TAK-931 sensitized resistant cells to Vemurafenib and reduced the number of cell colonies. Taken together, CDC7 overexpression and downregulation of miR-3613-3p were associated with Vemurafenib resistance in BRAFV600E- bearing melanoma cells. Dual targeting of CDC7 and BRAFV600E reduced the development of resistance against Vemurafenib. Further studies are warranted to investigate the clinical effect of targeting CDC7 in metastatic melanoma.Keywords
Funding Information
- Ministry of Higher Education of Egypt
This publication has 44 references indexed in Scilit:
- Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutationsBMC Cancer, 2013
- Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cellsOncogene, 2010
- Targeting the MAPK pathway in melanoma: Why some approaches succeed and other failBiochemical Pharmacology, 2010
- How do Cdc7 and cyclin-dependent kinases trigger the initiation of chromosome replication in eukaryotic cells?Genes & Development, 2010
- Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific Raf inhibitor PLX4032Journal of Translational Medicine, 2010
- Dbf4-Cdc7 Phosphorylation of Mcm2 Is Required for Cell GrowthJournal of Biological Chemistry, 2009
- Understanding Signaling Cascades in Melanoma†Photochemistry and Photobiology, 2007
- Identification and functional characterization of ASK/Dbf4 , a novel cell survival gene in cutaneous melanoma with prognostic relevanceCarcinogenesis, 2007
- Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cellsOncogene, 2006
- Mutations of the BRAF gene in human cancerNature, 2002